The Business Research Company’s report on the Glioma Treatment Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
Which emerging drivers are set to accelerate the growth of the glioma treatment market further?
The growing demand for personalized medicine is expected to propel the growth of the glioma treatment market going forward. Personalized medicine refers to a customized healthcare approach that takes into account individual patient traits, including genetics, environment, and lifestyle, to enhance treatment effectiveness and outcomes. The increasing demand for personalized medicine is driven by several factors, including advancements in genomics, patient empowerment, and improved treatment efficacy. The identification of biomarkers linked to gliomas helps predict treatment responses and outcomes, enabling the development of personalized treatment plans tailored to the unique characteristics of each patient. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Therefore, the growing demand for personalized medicine drives the growth of glioma treatment market.
Access Your Free Sample of the Global Glioma Treatment Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=10689&type=smp
What are the key factors influencing the forecasted market size of the glioma treatment industry?
The glioma treatment market size has grown strongly in recent years. It will grow from$5.06 billion in 2024 to $5.39 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to the risen incidence of gliomas, advancements in molecular understanding, evolution of standard therapies, clinical trials and research progress, and improved imaging and diagnostic techniques
The glioma treatment market size is expected to see strong growth in the next few years. It will grow to “$6.97 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to personalized therapies and biomarker discovery, immunotherapeutic advancements, integration of targeted therapies, the emergence of novel therapeutic platforms, and collaborative research initiatives. Major trends in the forecast period include blood-brain barrier penetrating agents, liquid biopsy for monitoring, focus on the quality of life and supportive care, genetic and molecular subtyping, patient advocacy and involvement.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=10689&type=smp
Who are the leading competitors in the glioma treatment market?
Major companies operating in the glioma treatment market include Merck & Co Inc., Amgen Inc., F Hoffmann-La Roche AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Arbor Pharmaceuticals LLC, Amneal Pharmaceuticals Inc., Karyopharm Therapeutics Inc., Bristol-Myers Squibb Co., Rigel Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Emcure Pharmaceuticals Ltd., Novartis AG, AstraZeneca plc, Eli Lilly and Company, Sanofi S.A., Johnson & Johnson, AbbVie Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Bayer AG, Gilead Sciences Inc., Ipsen Pharma, Eisai Co. Ltd., Genentech Inc., Iovance Biotherapeutics Inc., Agios Pharmaceuticals Inc.
Which emerging trends are set to transform the glioma treatment market landscape?
Product innovation is a key trend gaining popularity in the glioma treatment market. Major companies operating in the glioma treatment market are adopting new innovative products to sustain their position in the market. For instance, in June 2024, Servier Pharmaceuticals, a France-based pharmaceutical company, received FDA approval for VORANIGO (vorasidenib) tablets, marking a significant milestone as the first targeted therapy for Grade 2 IDH-mutant glioma. Vorasidenib is a dual inhibitor targeting isocitrate dehydrogenase (IDH) 1 and 2 mutations, which are commonly found in gliomas. These mutations lead to the production of 2-hydroxyglutarate (2-HG), a metabolite that promotes tumor growth and survival. By inhibiting these enzymes, vorasidenib reduces 2-HG levels, thereby potentially slowing tumor progression.
How do different geographies compare in terms of market share and growth potential in the glioma treatment market?
North America was the largest region in the glioma treatment market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global glioma treatment market report during the forecast period. The regions covered in the glioma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/glioma-treatment-global-market-report
Which major segments of the glioma treatment market are experiencing the fastest growth?
The glioma treatment market covered in this report is segmented –
1) By Type: Low-Grade, High-Grade
2) By Disease: Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Other Diseases
3) By Route Of Administration: Oral, Parenteral, Other Routes
4) By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Drug Therapy, Other Treatments
5) By End-User: Hospitals, Specialty Clinics, Other End Users
Subsegments:
1) By Low-Grade: Astrocytoma, Oligodendroglioma, Mixed Glioma
2) By High-Grade: Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10689
How is the glioma treatment market defined, and what are its core characteristics?
Glioma treatment refers to a treatment that reduces symptoms, removes and control the tumor and limits long-term damage to the brain or spinal cord. They are used to kills any glioma cells that might remain after surgery.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
